Akebia Therapeutics
AKBA

$1.44

2.09%

Market Cap: 302M

About: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Employees: 167

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

215% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 13

46% more call options, than puts

Call options by funds: $2.88M | Put options by funds: $1.97M

44% more capital invested

Capital invested by funds: $72.7M [Q4 2023] → $104M (+$31.7M) [Q1 2024]

33% more funds holding

Funds holding: 86 [Q4 2023] → 114 (+28) [Q1 2024]

13% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 24

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

1.82% less ownership

Funds ownership: 29.07% [Q4 2023] → 27.24% (-1.82%) [Q1 2024]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$5

247%

upside

Avg. target

$5.50

282%

upside

High target

$6

317%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Ed Arce	317%upside $6	Buy Maintained	28 Mar 2024
HC Wainwright & Co. Ed Arce	247%upside $5	Buy Reiterated	15 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about AKBA published over the past 30 days

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economics Announced Vafseo WAC pricing of $1,278 for a 30-day supply Submitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025 Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024 CAMBRIDGE, Mass.

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 517,000 shares of Akebia's common stock on June 28, 2024, including an option to purchase 500,000 shares to Erik Ostrowski, Akebia's newly hired Chief Financial Officer and Chief Business Officer.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C.

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer.

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m.

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20 th, 2024 at 3:00 p.m.

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Corporate Communications and IR John Butler - President and Chief Executive Officer Nicholas Grund - Chief Commercial Officer Conference Call Participants Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Hello, and welcome to the Akebia's First Quarter 2024 Financial Results Conference Call.

Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Akebia to host conference call at 8:00 a.m. ET on May 9 Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 Vafseo launch activities underway with availability expected in January 2025 Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023 CAMBRIDGE, Mass.

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

See News Rankings